Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

MagSense® Human Epidermal Growth Factor Receptor 2 (HER2) Imaging Agent (MSH2IA)

14. november 2026 opdateret af: Imagion Biosystems, Inc.

A Phase 1b/2 Study Investigating MagSense® Human Epidermal Growth Factor Receptor 2 (HER2) Imaging Agent (MSH2IA) Using Magnetic Resonance Imaging in Participants With HER2+ Breast Cancer for the Assessment of Tumor Involvement in the Lymph Nodes (MSH2IA Phase 1b/2 Study)

This Phase 1b/2 study is designed as an open-label, multicenter, 3 group, interventional study in which Phase 1b will evaluate the pharmacokinetics (PK) of MSH2IA and Phase 2 will confirm lowest effective dose as well as evaluate image timing, and diagnostic performance of a selected dose of MSH2IA when administered by subareolar or peritumoral injection.

No hypothesis testing is planned. Comparative statistics will be used to generate hypotheses to be tested in subsequent studies.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

70

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Florida
      • Miami, Florida, Forenede Stater, 33126
        • Rekruttering
        • Regis Clinical Research LLC
        • Ledende efterforsker:
          • Yilena Rodriguez Marrero, MD
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Inclusion Criteria:

  1. Female participants ≥18 years of age and are willing to provide written informed consent.
  2. In the opinion of the Investigator, willing and able to comply with required study procedures.
  3. Histologically confirmed primary HER2+ breast cancer; participants with a second primary tumor in the contralateral breast are eligible, but only 1 side will be evaluated.
  4. Primary tumor must be HER2+, defined according to ASCO/CAP 2018 guidelines as either IHC 3+ or IHC 2+ with confirmatory ISH-positive.
  5. Phase 1b and Phase 2 (Imaging Schedule) participants must be node suspicious by SOC assessment.
  6. No previous treatment of the primary tumor or ipsilateral axilla that includes surgery (other than biopsy), radiotherapy, or a biologic such as trastuzumab. In Phase 2 (Diagnostic Performance) only, participants who have received NCT are eligible if treatment has not included trastuzumab.
  7. Female participants of nonchildbearing potential: defined as either surgically sterilized (eg, hysterectomy, bilateral salpingectomy, bilateral oophorectomy ≥6 weeks before screening) or postmenopausal (ie, no menses for 12 months without an alternative medical cause.
  8. Female participants of childbearing potential are eligible to participate if not pregnant, not breastfeeding, and using birth control.

Exclusion Criteria:

Participants will be excluded from the study if ANY of the following criteria are applicable:

  1. Contraindications to the use of the Magtrace™ and Sentimag® Magnetic Localization System (Magtrace 2018), including use before NCT when MRI will be the primary imaging method for evaluation of breast cancer
  2. Previous or current diseases of Fe metabolism or history of adverse reactions to intravenous Fe products
  3. Known hypersensitivity to trastuzumab, iron oxide, or polyethylene glycol compounds
  4. Treatment by Herceptin® or biosimilar within prior six months
  5. Planned or prior use of Magtrace™ and Sentimag as a diagnostic agent, as it might interfere with MagSense® evaluations
  6. Known clinical or radiological evidence of distant metastases (Stage IV disease)
  7. Inflammatory breast cancer
  8. Prior surgical axillary procedure, including SLNB or ALND, or previous radiation on the ipsilateral side of the breast cancer primary
  9. Prior history of breast cancer in the ipsilateral breast
  10. Metal devices or fragments other than post-breast biopsy clips in the ipsilateral axilla or in the ipsilateral chest
  11. Any contraindications to MRI imaging

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Diagnostisk
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Phase 1b - MSH2IA Pharmacokinetics

Participants enrolled in Phase 1b will receive MSH2IA to evaluate its pharmacokinetic (PK) profile.

Imaging Agent intended as an adjunct to MRI for the assessment of axillary nodal disease in participants diagnosed with HER2+ primary breast cancer.

Eksperimentel: Phase 2 - MSH2IA Dose and Diagnostic Performance

Participants enrolled in Phase 2 will receive MSH2IA via subareolar or peritumoral injection to confirm the lowest effective dose, evaluate image timing, and assess the diagnostic performance of a selected dose of MSH2IA.

Imaging Agent intended as an adjunct to MRI for the assessment of axillary nodal disease in participants diagnosed with HER2+ primary breast cancer.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Phase 1b: Level of Fe in blood
Tidsramme: 24 hours post injection

PK MSH2IA Fe concentration > LLOQ in human whole blood

24 hours post injection
Phase 2 (Imaging Schedule): Dose and Imaging schedule for MSH2IA
Tidsramme: 24 hours post injection

MSH2IA dose to image suspicious versus normal nodes and Post dose MRI imaging timing

24 hours post injection
Phase 2 (Diagnostic Performance): Diagnostic performance comparison between MSH2IA and SOC
Tidsramme: 24 hours post injection

Patient level concordance of MSH2IA imaging to clinical pathology and Patient level concordance of MSH2IA to AxUS as measured by PPV, NPV, and Overall Predictive Concordance (PPV+NPV).

24 hours post injection

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Safety and Tolerability of MSH2IA Across All Phases
Tidsramme: From baseline through 1 year

All Phases: Assess safety and tolerability of MSH2IA Incidence and severity of AEs, serious adverse events and Injection site reactions (ISRs)

From baseline through 1 year

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

30. november 2026

Primær færdiggørelse (Anslået)

31. januar 2029

Studieafslutning (Anslået)

23. juli 2029

Datoer for studieregistrering

Først indsendt

13. oktober 2026

Først indsendt, der opfyldte QC-kriterier

13. oktober 2026

Først opslået (Faktiske)

21. oktober 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

14. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • IBI010105

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .